Trial Profile
A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Design Study to Evaluate the Effects of Perhexiline on ECG Parameters in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Jul 2021
Price :
$35
*
At a glance
- Drugs Perhexiline (Primary) ; Moxifloxacin
- Indications Hypertrophic cardiomyopathy
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Heart Metabolics Limited
- 02 Jul 2021 Results published in the Journal of Clinical Pharmacology
- 30 Aug 2017 Results (n=52) presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
- 08 Jun 2016 Status changed from active, no longer recruiting to completed.